These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30368658)

  • 1. Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.
    Zhou S; Wang Y; Wang L; Xie L; Chen J; Liu Y; Zhang H; Zhao Y; Ou N; Shao F
    Clin Drug Investig; 2019 Jan; 39(1):85-96. PubMed ID: 30368658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15-mg Tylerdipine Tablet in Healthy Chinese Male Volunteers.
    Wang L; Xie L; Zhou S; Wang Y; Chen J; Zhou Y; Liu Y; Zhang H; Tao M; Ou N; Shao F
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):126-132. PubMed ID: 30303628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
    Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
    Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.
    Mueller MS; Shakeri-Nejad K; Gutierrez MM; Krause A; Täubel J; Sanderson B; Dingemanse J
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):120-31. PubMed ID: 24126567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
    Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
    Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
    CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
    Richard M; Kaufmann P; Kornberger R; Dingemanse J
    Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
    Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
    CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human study to assess the safety, tolerability, and pharmacokinetics of intravenous SHPL-49 following single- and multiple-ascending-dose administration in healthy adults.
    Li S; Yang C; Wang W; Li J; Xu S; Zhao M; Xu C; Wang J; Wang Y
    J Pharm Biomed Anal; 2024 Oct; 249():116314. PubMed ID: 39033613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
    Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.
    Liu Y; Jia J; Liu G; Li S; Lu C; Liu Y; Yu C
    Clin Ther; 2009 Apr; 31(4):777-83. PubMed ID: 19446150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.
    Jing S; Liu W; Yang K; Lin Y; Yao X; Sun G
    Clin Transl Sci; 2023 Mar; 16(3):447-458. PubMed ID: 36495036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects.
    Hu C; Wang Y; Song R; Yu C; Luo X; Jia J
    Clin Drug Investig; 2017 Sep; 37(9):861-871. PubMed ID: 28695535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
    Jiang J; Tian L; Huang Y; Li Y; Xu L
    Clin Ther; 2008 Jul; 30(7):1290-9. PubMed ID: 18691988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.